EYPT - EyePoint Pharmaceuticals, Inc.

13.62
-0.360   -2.643%

Share volume: 764,199
Last Updated: 05-12-2026
Measuring And Control Equipment/Lab Analytical Instruments: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$13.98
-0.36
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
12%
Profitability 0%
Dept financing 20%
Liquidity 58%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.29%
1 Month
-6.20%
3 Months
5.26%
6 Months
18.33%
1 Year
130.46%
2 Year
11.46%
Key data
Stock price
$13.62
P/E Ratio 
0.00
DAY RANGE
$13.35 - $14.01
EPS 
-$3.51
52 WEEK RANGE
$5.35 - $19.11
52 WEEK CHANGE
$148.31
MARKET CAP 
1.075 B
YIELD 
N/A
SHARES OUTSTANDING 
83.841 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$934,645
AVERAGE 30 VOLUME 
$870,535
Company detail
CEO: Nancy S. Lurker
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Measuring And Control Equipment/Lab Analytical Instruments
Sector: Manufacturing

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Recent news